RougeTx, a spinout from Leiden University Medical Center, has secured $58 million in Series A funding to advance an oral small molecule treatment for hereditary hemorrhagic telangiectasia (HHT) into ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results